Ekaterina Wright

Ekaterina Wright

Auto-generated profile, based on publicly available information

Ekaterina Wright

Takeda Pharmaceutical Company Limited, Lexington, MA, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2022 in Journal of Medical Economics
Verified
Journal Article
Open access
SFSepehr Farahbakhshian
Sepehr Farahbakhshian
TITimothy J. Inocencio
Timothy J. Inocencio
GPGregory Poorman
Gregory Poorman
EWEkaterina Wright
Ekaterina Wright
RPRavi Pathak
Ravi Pathak
MBMichael Bullano
Michael Bullano
Type 1 Gaucher disease (GD1) is a rare inherited condition. Long-term enzyme replacement therapy (ERT) can reverse and prevent complications. Imiglucerase, taliglucerase alfa, and velaglucerase alfa are 3 ERTs used to treat GD1. In this study, we estimated how increasing uptake of velaglucerase alfa vs. the other ERTs would impact the budget of a hypothetical US healthcare plan. The results show that increased uptake of velaglucerase alfa is cost-saving for US health plans.